2017_SBRT_Course Book
Phase I study of alectinib in crizotinib-resistant ALK-positive NSCLC
„Good response but no cure“ Regular controls are necessary to detect new metastasis
Ou et al, Lancet Oncol 2014
Made with FlippingBook Annual report
Phase I study of alectinib in crizotinib-resistant ALK-positive NSCLC
„Good response but no cure“ Regular controls are necessary to detect new metastasis
Ou et al, Lancet Oncol 2014
Made with FlippingBook Annual report